Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small- is one of 9,000 studies in the ScholarPulse dataset. Key details — Authors: Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han; Journal / source: The Lancet; Year: 2015.
| Authors | Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han |
|---|---|
| Journal / source | The Lancet |
| Year | 2015 |
| Field | Cancer Immunotherapy and Biomarkers |
| Times cited | 6530 |
| Type | article |
| DOI / link | https://doi.org/10.1016/s0140-6736(15)01281-7 |